dc.contributor | Vall d'Hebron Barcelona Hospital Campus |
dc.contributor.author | Majem Tarruella, Margarita |
dc.contributor.author | García‑Martínez, E. |
dc.contributor.author | Martinez, M. |
dc.contributor.author | Rodriguez‑Abreu, D. |
dc.contributor.author | Alvarez, R. |
dc.contributor.author | Muñoz Couselo, Eva |
dc.date.accessioned | 2021-09-15T07:39:25Z |
dc.date.available | 2021-09-15T07:39:25Z |
dc.date.issued | 2020-02 |
dc.identifier.citation | Majem M, García-Martínez E, Martinez M, Muñoz-Couselo E, Rodriguez-Abreu D, Alvarez R, et al. SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019). Clin Transl Oncol. 2020 Feb;22:213–222. |
dc.identifier.issn | 1699-3055 |
dc.identifier.uri | https://hdl.handle.net/11351/6313 |
dc.description | Immunotherapy; Toxicity; irAEs |
dc.description.abstract | The use of immune checkpoint inhibitors has emerged as an effective treatment option for patients with several tumor types. By increasing the activity of the immune system, they can induce inflammatory side effects, which are often termed immune-related adverse events. These are pathophysiologically unique toxicities, compared with those from other anticancer therapies. In addition, the spectrum of the target organs is very broad. Immune-inflammatory adverse events can be life threatening. Prompt diagnosis and pharmacological intervention are instrumental to avoid progression to severe manifestations. Consequently, clinicians require new skills to successfully diagnose and manage these events. These SEOM guidelines have been developed with the consensus of ten medical oncologists. Relevant studies published in peer-review journals were used for the guideline elaboration. The Infectious Diseases Society of America grading system was used to assign levels of evidence and grades of recommendation. |
dc.language.iso | eng |
dc.publisher | Springer |
dc.relation.ispartofseries | Clinical and Translational Oncology;22 |
dc.rights | Attribution 4.0 International |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ |
dc.source | Scientia |
dc.subject | Immunoteràpia - Efectes secundaris |
dc.subject | Càncer - Tractament |
dc.subject | Protocols clínics |
dc.subject.mesh | Immunotherapy |
dc.subject.mesh | /adverse effects |
dc.subject.mesh | Neoplasms |
dc.subject.mesh | Practice Guidelines as Topic |
dc.title | SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019) |
dc.type | info:eu-repo/semantics/article |
dc.identifier.doi | 10.1007/s12094-019-02273-x |
dc.subject.decs | inmunoterapia |
dc.subject.decs | /efectos adversos |
dc.subject.decs | neoplasias |
dc.subject.decs | guías de práctica clínica como asunto |
dc.relation.publishversion | https://doi.org/10.1007/s12094-019-02273-x |
dc.type.version | info:eu-repo/semantics/publishedVersion |
dc.audience | Professionals |
dc.contributor.organismes | Institut Català de la Salut |
dc.contributor.authoraffiliation | [Majem M] Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, c/Sant Antoni Maria Claret 167, 08025 Barcelona, Spain. Spanish Group for Cancer Immuno-Biotherapy, GÉTICA, Madrid, Spain. [García-Martínez E] Department of Medical Oncology and Hematology, Hospital Universitario Morales Meseguer, Murcia, Spain. Spanish Group for Cancer Immuno-Biotherapy, GÉTICA, Madrid, Spain. [Martinez M] Department of Medical Oncology, Hospital del Mar, Barcelona, Spain. [Muñoz-Couselo E] Servei de Medicina Oncològica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Melanoma and Other Skin Tumors Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Rodriguez-Abreu D] Department of Medical Oncology, C.H.U. Insular-Materno Infantil de Gran Canaria, Las Palmas, Spain. Spanish Group for Cancer Immuno-Biotherapy, GÉTICA, Madrid, Spain. [Alvarez R] Department of Medical Oncology, Hospital Virgen de la Salud, Toledo, Spain |
dc.identifier.pmid | 31993963 |
dc.identifier.wos | 000514525700006 |
dc.rights.accessrights | info:eu-repo/semantics/openAccess |